Exelixis provides update on Genentech's pending New Drug Application for Cobimetinib
Exelixis’ partner Genentech informed Exelixis that, in order to accommodate its review of a supplemental data submission, the FDA has extended the PDUFA action date for its review of Genentech’s NDA for cobimetinib from Aug. 11, 2015 to Nov. 11, 2015. July 01, 2015